FDA Acts to Protect Newborn IV Nutrition

Why Is the FDA Acting on Newborn IV Nutrition Supplies?

Children's hospitals alerted the FDA that two outsourcing facilities supplying certain neonatal starter parenteral nutrition products were permanently shutting down. These preparations deliver nutrients through an intravenous line to newborns unable to receive adequate nutrition through their digestive system. The agency's September 4 announcement addresses an anticipated disruption; it does not establish that every hospital has already experienced a shortage. [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products).

The FDA issued guidance for immediate implementation describing temporary regulatory and enforcement priorities for specified compounded products. It covers qualifying outsourcing facilities, state-licensed pharmacies and federal facilities. This is a measure to maintain treatment access while longer-term supply arrangements are developed. Its practical effect will depend on hospitals obtaining suitable preparations from providers operating within the guidance's conditions. [FDA temporary compounding guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-starter-parenteral-nutrition-drug-products-neonates).

Why Do Premature Babies Need Starter Parenteral Nutrition?

Starter preparations provide pediatric amino acids and dextrose, supporting protein and energy needs during the first hours of care. Their standardized composition allows treatment to begin while an individualized formulation is prescribed and prepared. ASPEN's September 2 clinical considerations emphasize that starter nutrition is temporary and does not meet every infant's complete nutrient and electrolyte requirements. [ASPEN clinical considerations](https://nutritioncare.org/wp-content/uploads/2026/09/Clinical-Considerations-Neonatal-Starter-PN.pdf).

Timing matters because premature babies have fewer nutritional reserves than babies born at term. NICE explains that these infants can develop nutritional deficits more rapidly without support. Its neonatal guidance recommends starting parenteral nutrition promptly once indicated, within eight hours at the latest. That recommendation concerns babies who need intravenous nutrition; the decision depends on gestational age, illness and the ability to establish sufficient feeding through the digestive system. [NICE clinical rationale](https://www.nice.org.uk/guidance/NG154/chapter/rationale-and-impact).

How Can Hospitals Maintain Safe Nutrition During Supply Changes?

ASPEN recommends transition to patient-specific nutrition as soon as feasible, ideally within 24 hours and no later than 48 hours after birth. Its guidance also calls for assessment of pharmacy capacity before starting or expanding hospital compounding. Staff training, ingredient verification, suitable storage and pharmacist review remain essential when suppliers or preparation methods change. [ASPEN preparation and transition recommendations](https://nutritioncare.org/wp-content/uploads/2026/09/Clinical-Considerations-Neonatal-Starter-PN.pdf).

Monitoring continues after the infusion begins. NICE recommends checking blood glucose one to two hours after starting parenteral nutrition and after changing the bag, with additional checks when clinically indicated. Decisions about reducing intravenous nutrition also consider feeding tolerance, the nutrients supplied through feeding and the risks associated with continued intravenous access, including infection. For families, useful discussions with the neonatal team include why nutrition support is needed and how the feeding plan will progress. [NICE monitoring and feeding recommendations](https://www.nice.org.uk/guidance/NG154/chapter/recommendations).